23 min listen
SABCS 2019: Tucatinib: A New Standard of Care for HER2-Positive Metastatic Breast Cancer?
SABCS 2019: Tucatinib: A New Standard of Care for HER2-Positive Metastatic Breast Cancer?
ratings:
Length:
8 minutes
Released:
Apr 21, 2020
Format:
Podcast episode
Description
Dr. Rashmi Murthy, assistant professor of breast medical oncology at the University of Texas MD Anderson Cancer Center in Houston, discusses the results of the HER2CLIMB study that she presented at the 2019 San Antonio Breast Cancer Symposium showing that the experimental medicine tucatinib offers benefits to people diagnosed with HER2-positive metastatic breast cancer and may be a new standard of care.
Listen to the episode to hear Dr. Murthy explain:
a summary of the study results
why this study included people with brain metastases
the side effects of tucatinib
why she thinks the results are practice changing
Listen to the episode to hear Dr. Murthy explain:
a summary of the study results
why this study included people with brain metastases
the side effects of tucatinib
why she thinks the results are practice changing
Released:
Apr 21, 2020
Format:
Podcast episode
Titles in the series (100)
Hope After a Triple-Negative Breast Cancer Diagnosis: Author Patricia Prijatel discusses her book, Surviving Triple-Negative Breast Cancer by Breastcancer.org Podcast